Add BrightSurf on Google Email

Weight loss treatments linked to lower risk of obesity-related cancers in people without diabetes

A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·TypeObservational study·DateJun 7, 2026

New global analysis confirms alcohol’s complex relationship with health: clear cancer risks and chronic liver diseases at any level, mixed evidence for other cardiometabolic conditions

The study found high-risk associations between alcohol use and all ten cancers examined, with risk increasing progressively as intake rose. Low-to-moderate drinking was associated with lower disease risk for type 2 diabetes, Alzheimer's disease, ischemic heart disease, and stroke.

ASCO: Targeted therapy combo nearly doubles time without disease progression for patients with advanced colorectal cancer

A Phase 3 trial showed a 56% reduction in the risk of disease progression or death for patients with BRAF V600E mutant metastatic colorectal cancer treated with a targeted therapy combination. The treatment improved median progression-free survival and overall survival, with nearly 75% of patients alive at 18 months.

ASCO 2026: Ohio State researchers highlight cancer drug donation program, lung and breast cancer treatment, Lynch syndrome screening, access to clinical trials and more

Researchers from Ohio State University Comprehensive Cancer Center present new findings on a hospital program that redistributes unused oral cancer drugs donated by patients. The program helps patients avoid treatment delays caused by insurance issues, shipping problems or cost, and has been shown to reduce drug delays by six days.

A new AI model enables more efficient analysis of colorectal cancer samples

Researchers at the University of Jyväskylä have developed an AI model that can analyze colorectal cancer samples more efficiently and accurately predict the functioning of the cells' DNA repair mechanism. This could lead to shorter diagnosis times, reduced costs, and improved analysis accuracy.

SourceUniversity of Jyväskylä - Jyväskylän yliopisto·JournalComputer Methods and Programs in Biomedicine·DateMay 28, 2026

Colorectal cancer risk linked to gut microbiome alterations

A study by Harvard T.H. Chan School of Public Health found that gut microbiome alterations persist even after adenoma removal, increasing the risk of colorectal cancer. The researchers discovered that diet and physical activity were closely tied to CRC-associated gut microbes, suggesting lifestyle habits may contribute to sustained risk.

SourceHarvard T.H. Chan School of Public Health·JournalCell Host & Microbe·TypeObservational study·DateMay 27, 2026

Researchers identify drivers of resistance to KRAS inhibitors in colorectal cancer

Researchers at UT MD Anderson Cancer Center have uncovered genetic and cell-state adaptive mechanisms that drive resistance to KRAS inhibitors in patients with KRAS-mutant colorectal cancer. Targeting early inflammatory responses by adding TBK1 blockade may be a promising combination strategy to overcome treatment resistance.

Disease-causing pathogen rewires gut metabolism to secure nutrients for growth: Study

Researchers at Vanderbilt University Medical Center discovered that enterotoxigenic Bacteroides fragilis reshapes intestinal cell metabolism to support its growth, causing diseases like diarrhea and colorectal cancer. The study provides new possibilities for intervention by targeting metabolic interactions between host and microbes.

SourceVanderbilt University Medical Center·JournalCell·TypeExperimental study·DateApr 30, 2026

Bowel and ovarian cancer cases rising among younger adults in England

Cancer cases are on the rise among younger adults in England, with a significant increase in bowel and ovarian cancer rates. The study found that excess weight is a key contributor, but it's unlikely to fully explain this trend, as trends in risk factors such as smoking and diet have been stable or improving over the past decade.

SourceBMJ Group·JournalBMJ Oncology·TypeData/statistical analysis·DateApr 28, 2026

Young-onset colorectal cancer mortality by education

A nationwide study reveals that individuals with lower educational attainment are more likely to die from colorectal cancer at a younger age. The disparity in young-onset CRC mortality nearly doubled over the past three decades among those with 12 years or less education compared to those with 16 or more years of education.

SourceJAMA Network·JournalJAMA Oncology·DateApr 16, 2026

AACR: Targeted drug delivery for colorectal cancer, COVID-19’s impact on breast cancer outcomes, AI in cancer diagnosis and more

UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.

Researchers identify blood-based biomarker for cancer risk in people with Lynch Syndrome

A new blood-based biomarker has been discovered to help identify individuals at higher risk of developing cancer in people with Lynch Syndrome. The biomarker uses immune signatures detected in blood samples to provide unique characteristics that can detect cancer risk, allowing for early detection and personalized surveillance.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Communications·DateApr 6, 2026

First-in-class dual HIF inhibitors eliminate breast, colorectal, melanoma, and prostate tumors in mice when combined with immunotherapy

Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·TypeExperimental study·DateApr 2, 2026

Massey plays key role in helping create new therapeutic standard for patients with stage III colon cancer

A phase III clinical trial established a new treatment standard for patients with stage III colon cancer and deficient DNA mismatch repair. Immunotherapy drug atezolizumab showed significant benefits when added to chemotherapy, lowering the risk of cancer recurrence by 50%.

SourceVirginia Commonwealth University·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateApr 1, 2026

Targeting histone modifications in colorectal cancer: therapeutic potential of epigenetic modifiers on acetylation, methylation and phosphorylation

Epigenetic modifiers targeting histone acetylation, methylation, and phosphorylation show significant preclinical promise in CRC. Combination strategies and novel degraders offer pathways to overcome resistance, including PROTACs targeting KDM3A/B that eliminate cancer stem cells via Wnt/β-catenin inhibition.

SourceXia & He Publishing Inc.·JournalGene Expression·DateMar 26, 2026

Landmark Alliance ATOMIC Trial establishes new standard of care for patients with stage III dMMR colon cancer

The phase III Alliance ATOMIC trial shows that adding immunotherapy to standard chemotherapy improves clinical outcomes for patients with stage III dMMR colon cancer. The study found a 50% reduction in cancer recurrence risk and a 86.3% disease-free survival rate at three years.

SourceAlliance for Clinical Trials in Oncology·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 25, 2026

Colorectal cancer risk with negative colonoscopy or nonadherence after positive fecal occult blood test screening

A decrease in colorectal cancer incidence was observed among individuals with negative screening colonoscopy results, particularly men, suggesting risk-based follow-up strategies. Nonadherence to scheduled colonoscopies increased the risk of CRC, highlighting the need for targeted interventions to improve early detection.

SourceJAMA Network·JournalJAMA Network Open·DateMar 19, 2026

Aspirin not a quick fix for preventing bowel cancer

Daily aspirin use offers no quick or reliable way to prevent bowel cancer in the general population, increasing risk of serious bleeding. However, it may have potential long-term benefits for people at high genetic risk of colorectal cancer.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateFeb 25, 2026

Singapore study uncovers why some colorectal cancer tumors return and spread after chemotherapy

A Singapore study reveals that a specific gene called SERPINE1 drives resistance to chemotherapy and cancer spread in colorectal cancer patients. The findings also identify a molecular signature called RESIST-M, which can predict poorer survival and higher relapse risk, supporting earlier intervention and more targeted follow-up care.